

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. *Blood Adv.* 2019;3(7):980-983.

On line 6 of the first full paragraph in the right column on page 981 in the 9 April 2019 issue, “The median time to CR was 6 months (range, 3-24 months)” should read “The median time to CR was 6 months (range, 3-36 months).” Also, on the 2 last lines of the left column on page 982, “Six were complete responders, for whom time to best response ranged from 6 to 24 months” should read “Six were complete responders, for whom time to best response ranged from 6 to 36 months.” The errors have been corrected in the published article.

---

DOI 10.1182/bloodadvances.2019000319

© 2019 by The American Society of Hematology